| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT05908747 Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel… |
date change Completion pushed: 2026-05 -> 2026-12 |
| 2026-06-12 | NCT07560475 Exploratory Study of SHR-A1811 Via Different Administration Routes in Patients |
Trial arms changed: 2 -> 3 |
| 2026-06-05 | NCT07318831 Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for… |
Recruitment opened |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-09 | NCT07634978 Development and Application of an AI Chatbot for Perioperative Health Education in… | Recruiting | |
| 2026-06-08 | NCT07632118 Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following… | Phase 3 | Recruiting |
| 2026-06-04 | NCT07627464 Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma… | Phase 2 | Not Yet Recruiting |
| 2026-06-03 | NCT07622381 Specialist Nurse-Led Nursing Management for Patients Undergoing Head and Neck Cancer… | Recruiting | |
| 2026-05-27 | NCT07609641 Surgical Total Clearance Versus Extrahepatic Bile Duct Preservation for Biliary Tract… | Recruiting | |
| 2026-05-19 | NCT07594925 Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for… | Phase 2 | Recruiting |
| 2026-05-18 | NCT07591831 Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer | Phase 2 | Not Yet Recruiting |
| 2026-05-15 | NCT07589972 Neoadjuvant Trastuzumab, Pertuzumab Plus Metronomic Vinorelbine for Elderly HER2-Positive… | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07350928 | Observation of the Effect of Preoperative Use of Dexmedetomidine Hydrochloride Nasal… | Breast Cancer | Recruiting |
| NCT07632118 | Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following… | Pancreatic Cancer | Recruiting |
| NCT07436741 | Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in… | Pancreatic Cancer, Adult | Not Yet Recruiting |
| NCT07475026 | A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of… | HCC - Hepatocellular Carcinoma | Not Yet Recruiting |
| Phase 2 | |||
| NCT07304739 | Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT)… | Non Small Cell Lung Cancer | Recruiting |
| NCT06727617 | Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk Factors | Cervical Cancers | Recruiting |
| NCT07330037 | TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC… | NSCLC | Recruiting |
| NCT07330050 | WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC | NSCLC (Non-small Cell Lung Cancer) | Recruiting |
| NCT07340489 | Serplulimab for Locally Advanced Cervical Cancer | Cervical Cancer | Recruiting |
| NCT06951997 | QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer | Metastatic Pancreatic Cancer | Recruiting |
| NCT07397832 | CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL | Diffuse Large B-Cell Lymphoma (DLBCL) | Recruiting |
| NCT06452602 | Induction Immunochemotherapy Followed by Concurrent Chemoradiotherapy in Patients With… | Esophageal Cancer | Recruiting |
| NCT06208826 | A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in… | Head and Neck Cancer | Recruiting |
| NCT07457528 | Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally… | Resectable Esophageal Squamous Cell Carcinoma | Recruiting |
| NCT07505173 | Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain… | Naive Advanced Non-small Cell Lung Cancer With EGFR-sensitive Mutations (EGFR Exon 19 Deletion and Exon 21 L858R Mutation) and Symptomatic Brain Metastases | Recruiting |
| NCT07506109 | A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in… | BRAF V600E | Recruiting |
| NCT07528274 | Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line… | NSCLC (Non-small Cell Lung Cancer) | Recruiting |
| NCT07548060 | A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients… | NSCLC Stage IV | Recruiting |
| NCT07058948 | Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors | Solid Cancers | Recruiting |
| NCT07560488 | Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial… | HCC - Hepatocellular Carcinoma | Recruiting |
| NCT07012798 | FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body… | Hepatocellular Carcinoma (HCC) | Recruiting |
| NCT07594925 | Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for… | Rectal Cancer | Recruiting |
| NCT07038629 | Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC | Esophageal Cancer | Recruiting |
| NCT07162506 | DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI | Esophageal Cancer | Recruiting |
| NCT07281157 | Liposomal Irinotecan, Capecitabine and Enlonstobart With Short-Course Radiotherapy for… | Advanced Rectal Cancer | Recruiting |